Roey Ahram

Roey Ahram

Auto-generated profile, based on publicly available information

Roey Ahram

Division of Transplantation and Vascular Surgery, Department of Surgery, Seoul National University Hospital, Seoul

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2024 in International Journal of Surgery
Verified
Journal Article
Open access
AHAhram Han
Ahram Han
AJAe Jeong Jo
Ae Jeong Jo
HKHyunwook Kwon
Hyunwook Kwon
YKYoung Hoon Kim
Young Hoon Kim
JLJuhan Lee
Juhan Lee
SMSangil Min
Sangil Min
Background: The current study aimed to determine the optimal tacrolimus trough levels for balancing graft survival and patient safety following kidney transplantation. Materials and methods: We conducted a retrospective cohort study involving 11 868 kidney transplant recipients from five medical centers. The association between tacrolimus exposures (periodic mean trough level, coefficient of variability, time in therapeutic range) and composite allograft outcome (de novo donor-specific antibody, biopsy-proven rejection, kidney dysfunction, and graft failure), as well as safety outcomes (severe infection, cardiovascular events, malignancy, and mortality) were assessed. Data were sourced from Clinical Data Warehouses and analyzed using advanced statistical methods, including Cox marginal structural models with inverse probability treatment weighting. Results: Tacrolimus levels of 5.0–7.9 ng/ml and 5.0–6.9 ng/ml during the 2–12 month and 12–72 month post-transplantation periods, respectively, were associated with reduced risks of composite allograft outcomes. During the first post-transplant year, the adjusted hazard ratios (aHR) for composite allograft outcomes were 0.69 (95% CI 0.55–0.85, P<0.001) for 5.0–5.9 ng/ml; 0.81 (95% CI 0.67–0.98, P=0.033) for 6.0–6.9 ng/ml; and 0.73 (95% CI 0.60–0.89, P=0.002) for 7.0–7.9 ng/ml (compared to levels ≥8.0 ng/ml). For the 6-year composite outcomes, aHRs were 0.68 (95% CI 0.53–0.87, P=0.002) for 5.0–5.9 ng/ml and 0.65 (95% CI 0.50–0.85, P=0.001) for 6.0–6.9 ng/ml. These optimal ranges showed reduced rates of severe infection (6 years), malignancy (6 years), and mortality (1 year). Conclusion: This multicenter study provides robust evidence for optimal tacrolimus trough levels during the periods 2–12 and 12–72 months following kidney transplantation.